Nicoya, a main supplier of cutting edge expository instruments for the biotechnology and pharmaceutical businesses, will get warning administrations and up to $299,190 in innovative work subsidizing from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to build up a compact COVID-19 demonstrative test called Atlas.

This financing comes as a major aspect of a joint test gave by the Public Health Agency of Canada (PHAC) and the National Research Council of Canada (NRC) through the Innovative Solutions Canada (ISC) program. The spit based test will have the option to identify COVID-19 disease in under 20 minutes, with a simple to-utilize gadget that can be utilized in an assortment of settings.

<em>Accessibility continues to be a large barrier in achieving population testing goals. There is an urgent need for diagnostic kits that can provide users with immediate results, rather than having to rely on testing labs that can take two to five days. Delays increase the possibility of infected people spreading the virus further, or uninfected people facing unnecessary quarantine. Atlas will fill an important void in the current testing space, as a portable COVID-19 test that can fit seamlessly into economic re-opening strategies.”</em>
Ryan Denomme, Co-founder and CEO of Nicoya

Chart book will be a solitary use, dispensable gadget that will recognize dynamic disease by testing for SARS-CoV-2 viral proteins. To make the test as open as could be expected under the circumstances, Nicoya is driving it with cell phone innovation so it can convey lab-quality outcomes to an application in less than 20 minutes. The test will be performed with a salivation test, as opposed to the more typical nasopharyngeal swab tests. With Atlas, Nicoya plans to make testing increasingly accessible all over the place, from remote networks to cutting edge screening techniques.

As indicated by the World Health Organization, analytic testing for COVID-19 is basic to following the infection, understanding its the study of disease transmission, advising case the executives and smothering transmission. The NRC IRAP-ISC COVID-19 Challenge Program is assisting answers for fast testing in decentralized and purpose of-care settings.

<em>Our government is mobilizing resources to combat COVID-19 and I’m proud that Nicoya was one of four Phase I funding recipients of the Point-of-Care Diagnostic Test Kit Challenge. Nicoya is an exemplary company already working hard on pioneering innovative research and finding solutions together, and this approach is a pillar to ensuring we have both short and long-term solutions to fight the COVID-19 pandemic.”</em>Raj Saini, Member of Parliament for Kitchener Centre

With regards to their main goal to improve human life, Nicoya's biosensor arrangements have been empowering progressed logical exploration for quite a long time. The Nicoya group is presently utilizing its profound aptitude in territories, for example, nanotechnology, microfluidics and natural chemistry to create Atlas as a suitable answer for containing COVID-19 and forestalling the spread of future viral maladies.

The improvement of an Atlas model is in progress for Nicoya. "With this financing and backing, we have the chance to speed up innovative work of Atlas, and we're striving to carry it to general society as fast as could be expected under the circumstances," Denomme clarified.